TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01378650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Administration of Cilostazol 100mg twice a day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo one tablet matching for cilostazol twice a day for 4 weeks.
Study: NCT00742222

Intervention type: RADIATION
Group type: OTHER
Intervention: Electronic Brachytherapy
Description: 34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.

Intervention type: RADIATION
Group type: OTHER
Intervention: Intracavitary accelerated partial breast irradiation
Description: 3.4 Gy BID x 5 days
Study: NCT00723151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Milieu Communication Teaching
Description: Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Milieu Communication Teaching
Description: Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week
Study: NCT04163367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention as usual (IAU)
Description: Everything that's included in the social service units' regular handling of cases; such as the formal investigation and family treatment. The units cannot offer Safer Kids as a part of IAU.
Study: NCT00493610

Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylcysteine(Mucomyst)
Study: NCT01089569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: 5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
Study: NCT03352999

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fast track access to vaECMO
Description: ROHCA must be witnessed with onset of bystander CPR and an immediate call to Emergency Dispatch. Furthermore, to minimize any loss of time, all qualified geographical locations are directly incorporated in the regulation software of the center for medical emergency control.~Patients suitable for vaECMO implantation were identified as early as possible by the Medical Dispatcher at the Emergency Call Dispatch Center.~Bystanders pursued CPR until Mobile Intensive Care Unit (MICU) arrival. OHCA was considered refractory after 10 min of CPR initiating the transport by MICU to the hospital such that the vaECMO intervention could be performed. The resuscitation was pursued during the transfer to hospital. An automated chest compression device was used in order to minimize interruption periods.~The intensivists and cardiac surgeons stood ready to implant the vaECMO surgically in the catheterization laboratory where a percutaneous coronary intervention was subsequently performed.
Study: NCT00023933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody CC49-deltaCH2
Description: Given IV
Study: NCT03377816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: In a group setting participants will be encouraged to engage in art making for increased emotional awareness, expression, and acceptance. The role of the art therapist is to encourage a non-judgmental and exploratory approach to artmaking in which the process is emphasized over product. The art therapist obtains these goals by creating an atmosphere that is calm and by remaining tuned in to the verbalizations and body language of participants. If needed she can provide individual attention that is geared toward neutralizing concerns regarding performance during the art making.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Art Therapy
Description: In a group setting participants will engage in Mandala coloring
Study: NCT01089569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: 5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: .1 unit per kg to start, titrated based on Continuous Glucose Monitoring results

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: .1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
Study: NCT02003976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medial Opening Wedge High Tibial Osteotomy (HTO)
Description: A lower limb realignment surgery to redistribute load away from the most affected portion of the knee.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical Treatment Program
Description: A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Surgical Treatment Program
Description: A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
Study: NCT02762708

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Description: Subjects will be studied prior to surgical intervention and 12 weeks post surgery. Subjects in surgical arm will start diet intervention after surgery. Follow up with dietary will be per standard of care following RYGB surgery.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Caloric Restriction
Description: Subjects participating in caloric arm of this study will be asked to consume an identical diet that is controlled for caloric content and macronutrient composition. This is identical to that consumed by patient undergoing RYGB. Subjects in the caloric restriction arm will start the diet after the screening visit. Compliance will be monitored by alternating weekly meetings with a clinical psychologist and dietician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39
Description: A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery.
Study: NCT01463163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
Study: NCT00758069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: 100 mg once daily (QD), taken orally for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablet, QD, taken orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Sitagliptin
Description: 50 mg twice daily (BID), taken orally for 4 weeks
Study: NCT00179062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine versus risperidone
Description: Participants are to be randomized to olanzapine or risperidone. Antipsychotic medication will be given as per package insert daily for the twelve month duration of the trial.
Study: NCT01432457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained-release 50 mg/day
Description: 50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained-release 100 mg/day
Description: 100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
Study: NCT03123484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β-elemene
Description: β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
Description: EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
Description: EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual
Study: NCT03842501

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Release Supplement
Description: Calorie reduced diet plus Release supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Calorie reduced diet plus Placebo
Study: NCT00800930

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Butyrate
Description: Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
Study: NCT03292536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: \*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen\*~Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks
Study: NCT04173624

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endosonography
Description: Endosonography (EUS) is endoscopic method for evaluated pancreatic and biliary pathology.
Study: NCT04287985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose-VIS649
Description: Dose Level = Low
Study: NCT01402024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: The patient on study group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and~The patient with weight category of 41-65 kg in study group will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg
Study: NCT04173624

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Cholangiopancreatography
Description: Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for evaluating pancreatic and biliary pathology
Study: NCT01402024

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient on control group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and~The patient on control group with weight category of 41-65 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule).
Study: NCT00561340

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pediasure
Description: 50% will be randomized to pediasure with nutritional counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: 50% randomized to nutritional counseling only

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: 50% randomized to nutritional counseling only
Study: NCT03441555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib
Description: Intravenous
Study: NCT04415190

Intervention type: OTHER
Intervention: early palliative care
Description: early palliative care
Study: NCT01041066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: labetalol
Description: 0.4 mg/kg labetalol intravenously 4 min before intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicardipine
Description: 20 ㎍/kg nicardipine intravenously 4 min before intubation
Study: NCT04081766

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SUGAR Handshake
Description: An interactive patient counselling session delivered by a pharmacist which mainly focuses on medication-related instructions towards preventing hypoglycaemia in addition to recommendations about hypoglycemia early recognition, causes, and treatment. The SUGAR Handshake is individualised according to shared decision making and each participant's characteristics.~Components of the SUGAR Handshake intervention will be covered under five main domains:~1. Signs and symptoms of hypoglycemia.~2. Understanding the underlying causes of hypoglycaemia such as misuse of anti-diabetic medications.~3. Good glycaemic control and self-monitoring, which mainly includes instructions on handling the anti-diabetic medications.~4. Acknowledgement by the patient~5. Recap and summary~The pictogram contains the main recommendations for easy recall by the participant. Moreover, the intervention will be reinforced by a phone call at week 6 of the inclusion visit.
Study: NCT04100291

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Faecal microbiota transplantation
Description: FMT by daily enema with donor faeces

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by daily enema with placebo mixture
Study: NCT02511275

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal microdialysis
Description: Renal microdialysis is an innovative and promising technique in the monitoring of renal ischemia. Its sterile nature enables intraoperative use to give us real-time reflection of the in situ metabolism. In Patients who participated in clinical research with this microinvasive technique, no complications including bleeding has been reported.
Study: NCT02029456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
Study: NCT02603406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Study: NCT00222248

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training and bladder training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training and bladder training
Study: NCT04591145

Intervention type: OTHER
Intervention: Observational group
Description: Patient receive the standard bowel preparation strategy and routine colonoscopy
Study: NCT02293941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JKB-122 5mg
Description: Participants were randomized to receive JKB-122 5mg for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JKB-122 15mg
Description: Participants were randomized to receive JKB-122 15mg for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JKB-122 35mg
Description: Participants were randomized to receive JKB-122 35mg for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were randomized to receive comparable placebo for 12 weeks
Study: NCT05070000

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiologic examination
Description: Patients underwent US, CT or CT after US
Study: NCT00088621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 80mg tablet
Study: NCT04469010

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Bis-Glycinate Chelate and Vitamin C
Description: 28 mg iron 240 mg vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Bis-Glycinate Chelate
Description: 28 mg iron

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT02564146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel and gemcitabine
Description: Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel and gemcitabine
Description: Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
Study: NCT03540706

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Care with C-reactive protein assay in micro method
Description: Care with C-reactive protein assay in micro method
Study: NCT04574180

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental Crown
Description: Pediatric size dental crown; restore damaged tooth to its normal shape, size, and function.
Study: NCT02564146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine mono and nab-paclitaxel and gemcitabine
Description: Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.~Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.~Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
Study: NCT04287985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium Dose-VIS649
Description: Dose Level = Medium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose-VIS649
Description: Dose Level = High
Study: NCT01166165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 3 tablets of 1000 IU daily for 20 weeks
Study: NCT00695500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline tablets, 2 mg per day for 3 weeks
Study: NCT01166165

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 placebo tablets daily for 20 weeks
Study: NCT01830491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin 100mg
Study: NCT04849962

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in this group received a traditional muffin with butter as the predominant source of fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pecan
Description: Participants in this group received a muffin in which part of the butter was substituted out for pecans.
Study: NCT01342107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 114675A multi-purpose disinfecting solution (MPDS)
Description: Investigational multi-purpose disinfecting solution intended for use as a cleaning, reconditioning, rinsing, disinfecting, and storage solution for silicone hydrogel and soft contact lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft contact lens
Description: Soft hydrogel or silicone hydrogel contact lens matching subject's pre-study lens, including parameters, worn 16 hours on day of dispense.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft contact lens
Description: Soft hydrogel or silicone hydrogel contact lens matching subject's pre-study lens, including parameters, worn 16 hours on day of dispense.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blister pack solution
Description: Commercially approved storage solution as found in the contact lens blister pack.
Study: NCT02588950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500R

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500R

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500R

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500R